Biodexa Pharmaceuticals (BDRX) announced that it has partnered with Syngene for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa, Tanner Pharma launch global early access program for FAP patients
- Biodexa Pharmaceuticals Posts 2025 Preliminary Results and Deepens GI Cancer-Focused Pipeline
- Biodexa Pharmaceuticals management to meet with Maxim
- Biodexa Pharmaceuticals Announces Reverse ADR Split to Support Nasdaq Compliance
- Biodexa Pharmaceuticals announces one-for-five reverse ADR split